Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
60% of Japan Drug Makers See Lower Operating Profit in H1 FY2025, R&D Costs Weigh on Mid-Sized Firms
Roughly 60% of 24 major Japanese pharmaceutical companies posted year-on-year declines in operating profit for the first half of FY2025, with many mid-sized players citing higher R&D costs as the main driver, according to a Jiho tally. Net profit also…
To read the full story
Related Article
- Net Profit at 24 Japan Drug Makers Tops 2 Trillion Yen, Led by Astellas and Sumitomo
May 25, 2026
- 25 Japan Drug Makers’ Total Operating Profit Tops 2 Trillion Yen for 1st Time: Tally
May 20, 2025
- 25 Japan Drug Makers See 50% Growth in Operating Profit on FX, Unprofitability Re-Pricing
November 20, 2024
BUSINESS
- MSD Urges Swift Rollout of Routine HPV Vaccination for Males in Japan
July 29, 2026
- Drug Makers, Wholesalers Rush to Gauge Kumamoto Quake Impact
July 29, 2026
- Pfizer Brings Eisai into Nurtec Promotion in Japan
July 28, 2026
- Celltrion, Nippon Kayaku Broaden Alliance in Biopharma Biz
July 28, 2026
- Ishin Eyes Domestic Production of Allostem by August 2028
July 28, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…